EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

The Renal Impact of Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis

Anastasia T. Adamou

Aristotle University of Thessaloniki · 01.01.2026

DOI: 10.26262/heal.auth.ir.373661 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Aristotle University of Thessaloniki, erschienen am 01.01.2026. Verfasst von Anastasia T. Adamou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: The use of anticoagulants has been linked to anticoagulant-related nephropathy (ARN), a condition initially reported in patients treated with warfarin. However, cases have also been documented in patients receiving direct oral anticoagulants (DOACs). We conducted a systematic review and meta-analysis to assess the comparative effect of DOACs versus Vitamin K antagonists (VKAs) in renal function deterioration in atrial fibrillation (AF) population.

Methods

According to the PRISMA reporting guidelines for systematic reviews and meta-analyses, we performed a comprehensive search in PubMed/MEDLINE and EMBASE (via Scopus), focusing on studies in AF patients treated with DOACs or VKAs and assessing their renal function over time. The studied outcomes were 30% estimated glomerular filtration rate (eGFR) decline, progression to stage five chronic kidney disease (CKD) and doubling of serum creatinine.

Results

Among 4,566 records, 13 studies with 302,071 patients were included with an overall follow-up period of 701,421.5 patient years (mean: 2.3 years per patient). DOACs were associated with a lower risk of 30% eGFR reduction (HR:0.72, 95%CI:0.59–0.88), progression to stage five CKD (HR:0.49, 95%CI:0.37–0.64) and doubling of serum creatinine (HR:0.50, 95%CI:0.42–0.61). 30% eGFR reduction was also lower when apixaban, dabigatran and rivaroxaban were compared separately to VKAs, (HR:0.81, 95%CI:0.69–0.95), (HR: 0.61, 95% CI: 0.48–0.78) and (HR: 0.80, 95% CI: 0.70–0.92) respectively. There was no effect in progression to stage five CKD and doubling of serum creatinine, when apixaban was compared to VKAs.

Conclusions

This systematic review and metanalysis of 13 studies and >300,000 patients with atrial fibrillation followed for an overall period of >700,000 patient years showed that the deterioration of renal function is delayed in patients treated with DOACs compared to VKAs.

Schlagwörter

direct oral anticoagulantsvitamin K antagonistswarfarinatrial fibrillationanticoagulant-related nephropathyrenal functionestimated glomerular filtration rate declinechronic kidney disease progressionserum creatinine doublingapixaban

Zitieren

APA

Adamou, A. T. (2026). The Renal Impact of Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis. Aristotle University of Thessaloniki. https://doi.org/10.26262/heal.auth.ir.373661

Vancouver

Adamou AT. The Renal Impact of Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis. Aristotle University of Thessaloniki. 2026. doi:10.26262/heal.auth.ir.373661

BibTeX
@article{Adamou2026,
  author = {Adamou, Anastasia T.},
  title = {The Renal Impact of Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis},
  journal = {Aristotle University of Thessaloniki},
  year = {2026},
  doi = {10.26262/heal.auth.ir.373661}
}
Kostenlos starten →